Your genetic report shows MTHFR 677TT, and your homocysteine may be elevated even when folate and vitamin B12 appear adequate.

Most discussions of this variant focus almost entirely on folate. However, MTHFR does not depend on folate alone. The enzyme also requires FAD, a cofactor derived from riboflavin.

The MTHFR 677TT enzyme is less stable and has a greater tendency to lose its FAD cofactor. This makes its activity more sensitive to riboflavin status than the activity of the usual 677CC enzyme.

The practical significance of this interaction has been demonstrated in humans. In a randomized trial, a low nutritional dose of riboflavin reduced homocysteine in adults with the 677TT genotype, with the largest response among participants who had poorer riboflavin status at baseline.

This does not make 677TT a riboflavin-deficiency diagnosis. Many people with the genotype have normal homocysteine, while elevated homocysteine may also reflect folate or B12 insufficiency, reduced kidney function, thyroid dysfunction, medication effects, or several factors acting together.

The central question of this pattern is therefore:

Is MTHFR 677TT accompanied by a measurable riboflavin-sensitive homocysteine phenotype, or is another factor more important?

The combinations below are educational examples. They are not diagnostic criteria, and the same laboratory result may have several causes.

The riboflavin-sensitive hypothesis becomes more plausible when:

• the genotype is confirmed as MTHFR 677TT;
• fasting homocysteine is reproducibly elevated;
• folate and B12 have been assessed adequately;
• kidney function, thyroid function, medications, diet, smoking, and alcohol do not provide a stronger explanation;
• riboflavin intake or status appears inadequate or marginal;
• homocysteine changes in the expected direction after a documented low-dose riboflavin intervention under otherwise stable conditions.

The more of these features align, the stronger the case for a riboflavin-sensitive contribution.

MTHFR stands for methylenetetrahydrofolate reductase.

The enzyme converts:
5,10-methylenetetrahydrofolate → 5-methyltetrahydrofolate
5-methyltetrahydrofolate, or 5-MTHF, then provides the methyl group needed for the vitamin B12-dependent conversion of homocysteine back into methionine.

This means that folate-dependent remethylation requires several connected elements:

• an adequate folate pool;
• functional MTHFR;
• FAD bound to MTHFR;
• vitamin B12;
• methionine synthase;
• appropriate cellular and systemic conditions.

Riboflavin is vitamin B2.

The body converts riboflavin into:

• FMN, flavin mononucleotide;
• FAD, flavin adenine dinucleotide.

MTHFR uses FAD, not free riboflavin, as its flavin cofactor.
FAD helps the enzyme transfer reducing equivalents during the formation of 5-MTHF.

The common variant traditionally called MTHFR C677T is:

• rs1801133;
• currently described on a common reference transcript as c.665C>T;
• a substitution of alanine with valine at position 222, or p.Ala222Val.

People with the TT genotype carry two copies of the variant allele.
The variant enzyme is more thermolabile and has an increased tendency to lose its FAD cofactor.

This can reduce effective MTHFR activity, particularly when:

• riboflavin status is low;
• folate status is low;
• other parts of remethylation are also limited.

The 677TT enzyme is not absent.

It is less stable and more sensitive to its nutritional environment.

Increasing riboflavin availability may increase the probability that adequate FAD is available to the variant enzyme.

This may improve production of 5-MTHF and lower homocysteine in some people with the TT genotype.

That is the basis of the term:

Riboflavin-sensitive MTHFR 677TT.
It does not mean that riboflavin permanently repairs the gene or guarantees complete restoration of enzyme function.
Evidence: [A1, A2, B1].

The frequently repeated claim is that:

• 677CT reduces activity by approximately 30–40%;
• 677TT reduces activity by approximately 60–70%.

These figures originate largely from enzyme-activity studies performed under specific laboratory conditions.
They can help illustrate that TT has a stronger functional effect than CT.

They should not be interpreted as a precise personal measurement.

A statement such as:

“My methylation works at only 30%”
is not justified by the genotype.

The actual in vivo phenotype depends on:

• folate status;
• riboflavin status;
• FAD retention;
• B12 status;
• homocysteine production;
• kidney function;
• other genetic variation;
• age and health context;
• food fortification and supplement exposure.

Two people with 677TT can therefore have different:

• folate concentrations;
• homocysteine values;
• blood-pressure profiles;
• responses to riboflavin;
• clinical outcomes.

The genotype indicates a reproducible biochemical vulnerability.

It does not provide an individualized percentage of remaining whole-body methylation capacity.
Evidence: [A1, D1].

Riboflavin may be relevant, particularly when riboflavin status is inadequate and the more common explanations for elevated homocysteine have been addressed.

The strongest direct human evidence comes from a randomized intervention in adults selected by MTHFR genotype.
Participants received:

• 1.6 mg of ordinary riboflavin per day;
• or placebo;
• for 12 weeks.

Homocysteine fell specifically in the TT group.

The average reduction in the riboflavin-treated TT participants was approximately 22%.
Among TT participants with the lowest baseline riboflavin status, the reduction was larger approximately 40%.
No comparable homocysteine response was found in the CT or CC groups in that study.

This provides direct evidence that:

• the TT phenotype can be riboflavin responsive;
• baseline riboflavin status influences the size of the response;
• the effect is not simply a general response shared equally by all MTHFR genotypes.

What strengthens this interpretation?

• repeatedly elevated fasting homocysteine;
• confirmed 677TT;
• low or marginal riboflavin status;
• low dietary riboflavin intake;
• adequate folate;
• adequate B12 or no strong evidence of B12 deficiency;
• preserved kidney function;
• stable medications and supplements;
• a reproducible fall in homocysteine after riboflavin exposure.

What weakens it?

• severe folate deficiency;
• evidence of B12 deficiency;
• reduced eGFR;
• untreated hypothyroidism;
• medications that explain the result;
• substantial smoking or alcohol effects;
• high riboflavin exposure before testing;
• failure of homocysteine to change under interpretable conditions.

Interpretive takeaway

The direct riboflavin evidence is most relevant when MTHFR 677TT is accompanied by reproducibly elevated homocysteine.
The genotype alone does not establish that riboflavin is limiting.
Evidence: [B1].

Current evidence does not establish a need for a genotype-directed intervention when the relevant biochemical phenotype and another clinical indication are absent.

If the available findings include:

• confirmed 677TT;
• normal fasting homocysteine;
• adequate folate;
• adequate B12;
• no evidence of riboflavin deficiency;
• no relevant clinical problem being investigated,

the genetic result does not automatically create a supplement requirement.

It remains possible that the genotype influences selected metabolic details that are not captured by fasting homocysteine.

However, there is no validated clinical test showing that everyone with TT has impaired whole-body methylation despite normal biomarkers.

There is also no evidence that high-dose riboflavin in an asymptomatic person with normal homocysteine prevents:

• stroke;
• cognitive decline;
• depression;
• thrombosis;
• miscarriage;
• future “methylation failure.”

Interpretive takeaway

Normal homocysteine does not erase the genotype.
It does mean that its most established measurable consequence has not been demonstrated at the time of testing.
Evidence: [A3, A4, B1].

No.

It makes the possibility more relevant, especially with 677TT, but it does not prove it.
“Normal” folate and B12 results also require interpretation.

Folate may be normal after recent supplementation

Serum folate can rise quickly after:

• supplements;
• fortified foods;
• recent meals.

A normal or high result does not reconstruct the person’s status before supplementation.

Serum B12 may be misleading

Serum B12 can be influenced by:

• supplements;
• injections;
• binding proteins;
• liver disease;
• kidney disease;
• selected inflammatory or hematological conditions.

Methylmalonic acid and other context may be needed when B12 status is uncertain.

Homocysteine has many determinants

It can be influenced by:

• folate;
• B12;
• B6;
• riboflavin;
• kidney function;
• thyroid function;
• methionine intake;
• smoking;
• alcohol;
• age;
• medications;
• rare inherited disorders.

Interpretive takeaway

The combination of 677TT, adequate folate and B12, preserved kidney function, and elevated homocysteine creates a reasonable case for evaluating riboflavin as one possible contributor.
It does not make riboflavin the only possible explanation.

Not directly.

The principal randomized homocysteine trial included all three genotypes:

• CC;
• CT;
• TT.

The significant homocysteine response to 1.6 mg/day riboflavin was found in the TT group, not in the CT or CC groups.

This does not mean that a person with CT can never benefit from correcting genuine riboflavin deficiency.
Riboflavin is required regardless of genotype.

It means that the specific gene–nutrient response defining this pattern has been demonstrated most clearly in TT.

In a person with 677CT and elevated homocysteine, other relevant considerations include:

• folate;
• B12;
• kidney function;
• thyroid function;
• diet;
• alcohol;
• smoking;
• medications;
• general riboflavin deficiency.

Interpretive takeaway

Evidence from homozygous 677TT should not be converted automatically into a genotype-directed protocol for one-copy 677CT.
Evidence: [B1].

No.

MTHFR A1298C is a different variant located in another part of the enzyme.

It does not create the same well-characterized thermolabile FAD-loss phenotype as C677T.

Current public-health guidance states that there is not enough evidence to show that A1298C alone significantly affects folate processing.

People who carry one copy of C677T and one copy of A1298C are often described as compound heterozygous.

This genotype may influence MTHFR function, but the direct riboflavin-intervention evidence from 677TT should not be assumed to apply equally.

There is no equivalent randomized trial demonstrating that low-dose riboflavin specifically lowers homocysteine in:

• A1298C homozygotes;
• isolated A1298C heterozygotes;
• compound heterozygotes as a defined group.

Interpretive takeaway

A1298C and compound heterozygosity require phenotype-based interpretation.
They should not be inserted into a 677TT-specific model simply because all variants occur in the same gene.
Evidence: [A3, B1].

A fall in homocysteine strengthens the riboflavin-sensitive hypothesis, especially when:

• 677TT is confirmed;
• the homocysteine elevation was reproducible;
• the riboflavin dose and duration were documented;
• folate and B12 exposure remained stable;
• kidney and thyroid function remained stable;
• no other homocysteine-lowering intervention was introduced.

However, a response does not prove that:

• MTHFR was the sole cause;
• every tissue had impaired remethylation;
• all symptoms were caused by elevated homocysteine;
• long-term clinical risk has been eliminated;
• the same dose must be continued indefinitely.

Homocysteine also has biological and analytical variability.

A before-and-after comparison becomes more convincing when:

• both measurements were fasting;
• the same laboratory method was used;
• the interval and exposure were documented;
• no major dietary or medication change occurred;
• the result is reproducible.

Interpretive takeaway

A controlled biochemical response is one of the strongest practical clues available.
It remains evidence of contribution, not proof of a single complete explanation.

That statement is too broad.

A 2020 study compared one-carbon metabolites across MTHFR genotypes and also tested 1.6 mg/day riboflavin in adults with 677TT.

Before intervention, the TT group had:

• higher homocysteine;
• lower SAM;
• a lower SAM-to-SAH ratio

than the CC comparison group.

After riboflavin supplementation, the investigators observed increases in:

• SAM;
• cystathionine.

The study supports the idea that riboflavin can modify selected one-carbon metabolites in TT adults.

It does not establish that riboflavin:

• restores every methyltransferase reaction;
• normalizes DNA methylation in all tissues;
• increases neurotransmitter methylation;
• corrects “global undermethylation”;
• improves mood, cognition, or energy;
• produces the same effect in everyone with TT.

SAM and SAH measured in plasma are biochemical markers.
They are not a complete report of whole-body methylation activity.

The distinction that matters

The study showed a change in selected metabolites.
It did not validate “methylation restoration” as a clinical diagnosis or treatment outcome.
Evidence: [B2, C1].

The tests described below can provide pieces of evidence. None of them, alone or in combination, creates a formal diagnosis of a riboflavin-sensitive MTHFR disorder.

Genotyping can establish whether the result is:

• 677CC;
• 677CT;
• 677TT.

The common 677 variant is rs1801133
.
Some reports use:

• the historic C677T name;
• current HGVS nomenclature;
• reverse-strand letters;
• plus/minus symbols.

The report should be interpreted using the SNP identifier and laboratory explanation rather than relying only on a color or a “mutation severity” score.

Most useful for

• establishing whether the direct TT-specific intervention evidence is relevant.

It does not measure

• current MTHFR enzyme activity;
• FAD binding;
• folate availability;
• homocysteine;
• current riboflavin status;
• overall methylation capacity;
• whether supplementation is necessary.

Important clinical boundary

Major genetics guidance advises against routine common-MTHFR testing as part of a thrombophilia evaluation because the result generally does not change management.
This pattern is most useful when TT is already known and a compatible phenotype is being investigated.
It is not an argument for screening every person with nonspecific symptoms.

The erythrocyte glutathione reductase activation coefficient, or EGRAC, is a functional test of riboflavin status.

Glutathione reductase requires FAD.

The laboratory measures enzyme activity:

• before added FAD;
• after added FAD.

When the enzyme responds strongly to added FAD, the activation coefficient is higher, suggesting poorer riboflavin status.

Frequently used interpretive categories are approximately:

• EGRAC ≤1.2: adequate;
• 1.2–1.4: marginal;
• 1.4: deficient.

These cutoffs are not universally standardized.

Advantages

EGRAC has shown sensitivity to changes in riboflavin intake in supplementation studies.

Limitations

• it is not widely available in routine clinical laboratories;
• laboratory protocols vary;
• it may be unsuitable or difficult to interpret in glucose-6-phosphate dehydrogenase deficiency;
• it does not directly measure FAD occupancy of MTHFR.

Interpretive takeaway

EGRAC is useful in nutrition research and selected specialist settings.
It is not a routine “MTHFR function test.”
Evidence: [C2].

Plasma riboflavin can be measured by specialized clinical laboratories.

Most useful for

• detecting clearly low circulating riboflavin;
• confirming recent exposure;
• monitoring status in selected situations.

Important limitations

Plasma riboflavin can rise after:

• recent food intake;
• a supplement;
• a fortified drink.

Testing protocols may require:

• fasting;
• rapid processing;
• protection from light.

A nonfasting or recently supplemented result may be elevated and difficult to interpret as baseline status.

Plasma riboflavin does not directly measure:

• intracellular FAD;
• FAD bound to MTHFR;
• long-term tissue status;
• response of the variant enzyme.

Whole-blood B2 testing is also offered by some reference laboratories.

It may provide additional information, but:

• methods are laboratory specific;
• reference intervals are method specific;
• the result is not interchangeable with EGRAC;
• it has not been validated as a direct predictor of riboflavin-responsive homocysteine in 677TT.

The practical limitation

There is no universally available clinical test that directly reports:
“MTHFR is losing FAD and will respond to a specific dose of riboflavin.”
The interpretation remains based on combined evidence.
Evidence: [A2, A6, C2].

Folate status matters because the 677TT phenotype is more apparent when folate availability is low.

Useful measurements may include:

• serum folate;
• RBC folate in selected settings.

A low folate result can independently raise homocysteine.

A riboflavin intervention should not be expected to replace genuine folate correction.
A normal serum folate result after supplementation does not necessarily show what folate status was before treatment.

The 5-MTHF produced by MTHFR is used in the vitamin B12-dependent methionine synthase reaction.

If B12 is genuinely inadequate:

• homocysteine may remain elevated;
• producing more 5-MTHF may not remove the main bottleneck.

Useful context may include:

• serum B12;
• methylmalonic acid;
• holotranscobalamin where available;
• CBC and MCV;
• diet, medications, and absorption risk.

A normal MMA makes a substantial general B12 deficiency less likely.
It does not directly measure methionine synthase activity in every tissue.

Reduced kidney function is an important cause of elevated homocysteine.

Riboflavin may modify one component of the pathway without normalizing a kidney-related elevation.

Creatinine and eGFR therefore provide essential context before persistent high homocysteine is attributed primarily to MTHFR.

Hypothyroidism can be associated with higher homocysteine through several possible mechanisms, including effects on metabolism and kidney function.

Thyroid testing may be particularly relevant when elevated homocysteine occurs together with compatible clinical findings.

The symptoms themselves remain nonspecific.

Blood pressure is easily measurable and clinically important.

However, it should not be used as a direct test of MTHFR activity.

Possible interpretation:

• 677TT + hypertension defines a population in which riboflavin has been studied;
• normal blood pressure does not exclude a homocysteine phenotype;
• high blood pressure does not prove a riboflavin-sensitive mechanism.

Home and ambulatory measurements can help distinguish persistent hypertension from an isolated clinic value.

Even a combination of genotype, homocysteine, folate, B12, and riboflavin status cannot directly show:

• the proportion of MTHFR molecules retaining FAD;
• real-time MTHFR flux;
• tissue-specific production of 5-MTHF;
• methylation activity in the brain;
• neurotransmitter methylation;
• global DNA methylation;
• future disease risk for one individual;
• which symptom is caused by the genotype;
• which riboflavin form will be best tolerated;
• whether supplementation must continue indefinitely.

Routine tests provide:

• genotype;
• concentrations;
• selected functional biomarkers.

They do not provide a live measurement of the whole one-carbon network.

This is the clearest version of the research pattern.

Possible configuration:

• confirmed 677TT;
• elevated homocysteine;
• low or marginal riboflavin status;
• adequate folate;
• adequate B12;
• preserved kidney function;
• homocysteine falls after low-dose riboflavin.

The main modifiable factor may be insufficient FAD availability for a vulnerable enzyme.

Possible configuration:

• confirmed TT;
• low folate;
• elevated homocysteine;
• low or adequate riboflavin.

Both factors may contribute.

The 677TT enzyme has reduced functional resilience when folate status is poor.
The immediate problem should not automatically be reframed as riboflavin deficiency when folate is clearly low.

Possible configuration:

• elevated homocysteine;
• low or borderline B12;
• elevated MMA;
• normal or high folate;
• neurological or hematological context.

Here, increasing MTHFR-supported 5-MTHF production cannot replace the missing B12-dependent methionine synthase function.

Possible configuration:

• elevated homocysteine;
• reduced eGFR;
• normal folate and B12;
• 677TT present incidentally or as a secondary contributor.

The genotype may influence the size of the elevation without being the primary cause.

Possible contributors include:

• hypothyroidism;
• smoking;
• high alcohol exposure;
• selected medications;
• low physical activity;
• several moderate factors acting together.

A riboflavin response may be partial because the pattern is mixed.

Possible configuration:

• confirmed TT;
• normal homocysteine;
• adequate folate and B12;
• no hypertension;
• nonspecific symptoms not explained by objective markers.

The genotype is real.

The proposed riboflavin-sensitive clinical problem has not been demonstrated.

A person with CC or CT can still have inadequate riboflavin status.

Possible manifestations may include:

• angular cheilitis;
• glossitis;
• sore throat;
• dermatitis;
• anemia in selected contexts;
• combined nutrient deficiencies.

Correcting a genuine deficiency is different from interpreting a TT-specific MTHFR phenotype.

The sequence below is an educational framework for organizing evidence. It is not a diagnostic or treatment protocol.

1. Is the genotype truly 677TT?
2. Is fasting homocysteine reproducibly elevated?
3. Is folate genuinely adequate?
4. Has B12 been evaluated adequately?
5. Are kidney and thyroid function relevant?
6. Is riboflavin intake or status inadequate?
7. What outcome was measured in the relevant research?
8. Did that outcome change under interpretable conditions?

Only after these questions are addressed does a genotype-targeted explanation become useful.

The two forms most commonly discussed in supplements are:

• ordinary riboflavin;
• riboflavin 5′-phosphate, often abbreviated R5P.

Riboflavin 5′-phosphate is essentially an FMN form.

It is not:

• “methylated riboflavin”;
• FAD;
• the direct cofactor bound by MTHFR.

The main homocysteine trial used ordinary riboflavin.

It did not compare:

• ordinary riboflavin with R5P;
• riboflavin with FAD;
• different supplement brands;
• liquid with tablets;
• low dose with high dose.

Products may differ in:

• dose;
• formulation;
• other B vitamins;
• excipients;
• timing;
• individual tolerance.

A subjective difference does not establish superior FAD delivery.

Interpretive takeaway

Ordinary riboflavin is the form used in the key TT-specific trials.
No equivalent 677TT-specific trial has shown that R5P produces a greater homocysteine response.
Evidence: [A2, B1, B2, U].

One of the largest gaps between the scientific literature and online recommendations involves dosage.

The primary homocysteine trial used:

1.6 mg riboflavin per day

The intervention lasted 12 weeks.

A later one-carbon-metabolite trial also used:

1.6 mg per day

for 16 weeks.

Several targeted blood-pressure studies used similarly low nutritional doses.

The 1.6 mg dose is reported here because it was the dose tested in the principal trials. It should not be interpreted as a personalized recommendation or as an established treatment dose for every person with 677TT.

How does this compare with ordinary requirements?

Approximate adult recommended intakes are:

• men: 1.3 mg/day;
• women: 1.1 mg/day;
• pregnancy: 1.4 mg/day;
• lactation: 1.6 mg/day.

The trial dose was therefore close to ordinary nutritional requirements.

It was not a pharmacological megadose.

How does this compare with commercial products?

Many supplements contain:

• 25 mg;
• 50 mg;
• 100 mg;
• 200 mg

per serving.

These doses are many times greater than the dose used to demonstrate the TT-specific homocysteine effect.

Does a larger dose work better?

There is no direct evidence that:

• 25 mg works better than 1.6 mg;
• 100 mg restores more MTHFR activity;
• 400 mg is necessary for 677TT;
• a stronger subjective reaction indicates a stronger therapeutic effect.

Riboflavin absorption is saturable. The body absorbs relatively little from a single dose above approximately 27 mg, and excess absorbed riboflavin is readily excreted.

What is known about high-dose safety?

No tolerable upper-intake level has been established because riboflavin has low observed toxicity and even 400 mg/day has not produced a consistent toxicity signal in available studies.

However:

• safety data at high exposure remain limited;
• absence of an established UL does not mean unlimited dosing is evidence based;
• high doses used for migraine belong to a different indication;
• high-dose migraine evidence cannot be transferred to MTHFR 677TT.

Interpretive takeaway

The genotype-specific evidence is based on a nutritional dose.
Commercial capsule strength should not be mistaken for a scientifically established requirement.
Evidence: [A2, B1, B2].

The direct riboflavin evidence discussed in this pattern applies most clearly to people with the MTHFR 677TT genotype.

It should not be transferred automatically to:

• 677CT;
• A1298C;
• compound heterozygosity involving one 677T allele and one A1298C allele.

These genotypes occur in the same gene, but they do not create identical biochemical effects.

People with 677CT carry one copy of the usual 677C allele and one copy of the 677T allele.

The enzyme may show an intermediate reduction in activity under laboratory conditions, but the phenotype is generally less pronounced than in 677TT.

In the principal randomized riboflavin trial:

• participants with 677TT showed a significant reduction in homocysteine;
• participants with 677CT did not show the same genotype-specific response;
• participants with 677CC also did not show the same response.

This does not mean that riboflavin is irrelevant to people with 677CT.

Riboflavin remains an essential nutrient for everyone, and a genuine riboflavin deficiency can affect multiple flavin-dependent enzymes regardless of MTHFR genotype.

It means that the specific evidence supporting a riboflavin-sensitive MTHFR phenotype is strongest for 677TT.

When 677CT is accompanied by elevated homocysteine, other explanations still require careful consideration, including:

• low folate;
• vitamin B12 insufficiency;
• reduced kidney function;
• hypothyroidism;
• medications;
• smoking;
• alcohol;
• low dietary riboflavin;
• several interacting factors.

Interpretive takeaway

The presence of one 677T allele does not justify applying the 677TT trial results as though the genotypes were equivalent.
The laboratory phenotype remains more important than the genotype alone.
Evidence: [B1].

No.

MTHFR A1298C is a different common variant located in another region of the MTHFR enzyme.
It does not produce the same well-characterized thermolabile enzyme or the same increased tendency to lose FAD that has been demonstrated for C677T.

A1298C may influence MTHFR function, but its effect is generally different and less consistently associated with elevated homocysteine.

Current public-health guidance states that there is insufficient evidence that A1298C alone substantially affects folate processing.

There is no equivalent randomized trial showing that riboflavin specifically lowers homocysteine in people with:

• one A1298C allele;
• two A1298C alleles;
• A1298C without 677TT.

Interpretive takeaway

The riboflavin-sensitive 677TT model should not be used as a general protocol for A1298C.
A1298C requires interpretation together with the actual laboratory phenotype rather than by analogy with 677TT.
Evidence: [A1, A3, B1].

Compound heterozygosity usually means that a person carries:

• one 677T allele;
• one A1298C allele.

This combination may reduce MTHFR function more than either single heterozygous variant alone in some individuals.

However, it is still not identical to 677TT.

The available riboflavin trials did not establish a specific homocysteine-lowering effect for compound heterozygotes as a separate group.

The practical interpretation should therefore focus on:

• fasting homocysteine;
• folate status;
• vitamin B12 status;
• kidney function;
• thyroid function;
• riboflavin intake or status;
• other relevant clinical factors.

The term “compound heterozygous” can sound more severe than the biochemical phenotype actually is.
It describes the genotype, not the degree of functional impairment in a particular person.

Interpretive takeaway

Compound heterozygosity may provide useful genetic context, but it does not automatically establish the same riboflavin-sensitive phenotype demonstrated in 677TT.

The central distinction is:

The genotype identifies a possible vulnerability. The laboratory phenotype shows whether that vulnerability is currently visible.

The strongest riboflavin-specific evidence remains limited to MTHFR 677TT.

Several explanations deserve consideration.

The genotype may be present without a riboflavin-sensitive phenotype.

MTHFR cannot produce adequate 5-MTHF if the folate pool is inadequate.

Producing more 5-MTHF cannot complete remethylation if B12 is insufficient.

A riboflavin-responsive MTHFR component may be too small to overcome a renal effect.

The pattern may have more than one cause.

The largest homocysteine response in the principal trial occurred among TT participants with the poorest starting riboflavin status.

A mildly elevated homocysteine result may fluctuate.
Repeat testing and consistent conditions matter.

If riboflavin, methylfolate, B12, TMG, choline, creatine, and diet all changed, the result cannot be assigned to riboflavin.

Riboflavin may alter homocysteine without improving:

• anxiety;
• fatigue;
• cognition;
• sleep;
• mood;
• exercise tolerance.

Interpretive takeaway

Failure of homocysteine to change should weaken or complicate the original riboflavin-sensitive hypothesis.
It does not automatically indicate that a higher dose, R5P, or FAD is required.

Public discussions describe reactions such as:

• anxiety;
• irritability;
• insomnia;
• racing thoughts;
• restlessness;
• headache;
• fatigue;
• sleepiness;
• palpitations;
• feeling unusually stimulated;
• worsening compulsive behavior.

These reports are important as observations.

They have not established a specific riboflavin-MTHFR reaction syndrome.

A 50 or 100 mg capsule is not equivalent to the 1.6 mg used in the main trial.

Many B2 products are part of a B-complex containing:

• methylfolate;
• B12;
• B6;
• niacin;
• thiamine;
• pantothenic acid;
• herbal or stimulating ingredients.

The reaction cannot automatically be attributed to riboflavin.

Temporal association does not always mean direct causation.

FMN and FAD support numerous enzymes involved in:

• energy metabolism;
• fatty-acid oxidation;
• glutathione reductase;
• vitamin B6 activation;
• tryptophan metabolism;
• monoamine oxidase reactions.

A change in mood or sleep cannot be localized to MTHFR on the basis of symptoms alone.

Possibilities include:

• excipients;
• sweeteners;
• flavoring agents;
• another vitamin;
• the combined dose.

A negative reaction does not automatically prove:

• “overmethylation”;
• excessive MTHFR activation;
• a rapid rise in SAM;
• depletion of another B vitamin;
• slow COMT;
• slow or fast MAOA;
• excessive dopamine or serotonin breakdown;
• a therapeutic startup reaction;
• that treatment is working;
• that R5P would necessarily be better;
• that ordinary riboflavin would necessarily be better.

A temporal reaction suggests that the product, exposure, timing, combination, or underlying context may require reconsideration.
The reaction alone does not identify the biochemical mechanism.
Evidence: [A2, U].

• Is the genotype definitely MTHFR 677TT?
• Does the report use rs1801133 or another clear identifier?
• Is fasting homocysteine elevated more than once?
• Were homocysteine tests performed under comparable conditions?
• Were supplements taken before testing?
• Is folate clearly low, normal, or high because of supplementation?
• Has B12 been assessed with enough context?
• Is MMA relevant?
• Are creatinine and eGFR adequate?
• Could hypothyroidism explain part of the result?
• Are smoking, alcohol, medications, or diet contributing?
• Is riboflavin intake plausibly inadequate?
• Was riboflavin status assessed with plasma, whole blood, or EGRAC?
• Could the B2 result mainly reflect recent supplementation?
• Is the person TT, or are TT data being applied to CT or A1298C?
• What dose was used in the relevant study?
• How does a commercial product compare with the 1.6 mg studied dose?
• Was ordinary riboflavin used, or a multi-ingredient R5P product?
• Were folate, B12, TMG, choline, and other supplements changed at the same time?
• What was the intended research or monitoring outcome: homocysteine, blood pressure, riboflavin status, or symptoms?
• Did the objective marker change?
• Did symptoms and laboratory results move in the same direction?
• Is high blood pressure being assessed independently rather than attributed only to MTHFR?
• Is established pregnancy guidance being replaced by an unvalidated genetic protocol?
• What finding would make the riboflavin-sensitive interpretation less likely?

These are different questions. They require different evidence and may lead to different conclusions.

Is the genotype definitely MTHFR 677TT?
Does the report use rs1801133 or another clear identifier?
Is fasting homocysteine elevated more than once?
Were homocysteine tests performed under comparable conditions?
Were supplements taken before testing?
Is folate clearly low, normal, or high because of supplementation?
Has B12 been assessed with enough context?
Is MMA relevant?
Are creatinine and eGFR adequate?
Could hypothyroidism explain part of the result?
Are smoking, alcohol, medications, or diet contributing?
Is riboflavin intake plausibly inadequate?
Was riboflavin status assessed with plasma, whole blood, or EGRAC?
Could the B2 result mainly reflect recent supplementation?
Is the person TT, or are TT data being applied to CT or A1298C?
What dose was used in the relevant study?
How does a commercial product compare with the 1.6 mg studied dose?
Was ordinary riboflavin used, or a multi-ingredient R5P product?
Were folate, B12, TMG, choline, and other supplements changed at the same time?
What was the intended research or monitoring outcome: homocysteine, blood pressure, riboflavin status, or symptoms?
Did the objective marker change?
Did symptoms and laboratory results move in the same direction?
Is high blood pressure being assessed independently rather than attributed only to MTHFR?
Is established pregnancy guidance being replaced by an unvalidated genetic protocol?
What finding would make the riboflavin-sensitive interpretation less likely?
These are different questions. They require different evidence and may lead to different conclusions.

High-confidence sources

[A1] MTHFR 677C>T mechanism and FAD instability

Sources:

Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics. 1995;10:111–113. PMID: 7647779.
Yamada K, Chen Z, Rozen R, Matthews RG. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:14853–14858. PMID: 11742092.
Source type: original genetic discovery and recombinant-enzyme mechanistic research.
Used to support:

• identification of the common thermolabile MTHFR variant;
• p.Ala222Val substitution;
• reduced stability of the variant enzyme;
• increased propensity for FAD dissociation;
• differences between C677T and A1298C.

Does not establish:

• a personal percentage of whole-body methylation impairment;
• symptom causation;
• a universal supplement requirement;
• complete restoration by riboflavin.

Why level A for mechanism: the variant and its flavin-sensitive enzyme properties are well characterized and repeatedly incorporated into later human research.


[A2] Riboflavin physiology, intake, forms, and safety

Source:
National Institutes of Health, Office of Dietary Supplements. Riboflavin: Fact Sheet for Health Professionals.
Source type: official evidence-based nutritional reference.
Used to support:

• riboflavin as the precursor of FMN and FAD;
• dietary sources;
• recommended intakes;
• limited absorption from large single doses;
• similarity in bioavailability among free riboflavin, FMN, and FAD from foods;
• absence of an established tolerable upper-intake level;
• the need for caution despite low observed toxicity.

Does not establish:

• a high-dose protocol for MTHFR 677TT;
• superiority of R5P;
• symptom improvement from riboflavin;
• unlimited safety at any dose or duration.

Why level A: official synthesis of established nutritional physiology and safety data.

[A3] Common MTHFR variants, folic acid, and pregnancy

Source:
US Centers for Disease Control and Prevention. MTHFR Gene Variant and Folic Acid Facts. Updated May 27, 2025.
Source type: official public-health guidance.
Used to support:

• the ability of people with common MTHFR variants to process folic acid;
• the average approximately 16% lower blood-folate concentration in TT compared with CC at similar intake;
• the importance of folic-acid intake over genotype for blood folate;
• the recommendation for 400 mcg folic acid daily for people who could become pregnant;
• insufficient evidence that A1298C alone meaningfully alters folate processing.

Does not establish:

• that genotype never affects folate metabolism;
• equivalence of every folate form for every outcome;
• a riboflavin treatment protocol during pregnancy.

Why level A: current official public-health interpretation of the common variants and neural-tube-defect prevention.


[A4] Clinical utility of common MTHFR testing

Sources:
Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genetics in Medicine. 2013;15:153–156. PMID: 23288205.
Bashford MT, et al. Addendum: ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genetics in Medicine. 2020;22:2125. PMID: 32533132.
Source type: professional genetics guidance.
Used to support:

• minimal clinical utility of routine common-MTHFR testing;
• recommendation against using common MTHFR polymorphisms as part of routine thrombophilia evaluation;
• separation of genotype from clinically meaningful phenotype.

Does not establish:

• that 677TT has no biochemical effect;
• that known TT status can never help interpret homocysteine or nutrition research.

Why level A: formal professional guidance on test use and clinical interpretation.


[A5] Current systematic assessment of blood-pressure evidence

Source:
Bradbury KE, Coffey S, Earle N, Ni Mhurchu C, Jull AB. Riboflavin supplements for blood pressure lowering in adults. Cochrane Database of Systematic Reviews. 2025;10:CD015464. PMID: 41123035.
Source type: systematic review of randomized controlled trials.
Participants: four trials with 374 participants.
Used to support:

• the conclusion that the effect of oral riboflavin on systolic and diastolic blood pressure remains very uncertain;
• small samples and high risk of bias in most included trials;
• the need for larger, well-conducted studies.

Does not establish:

• that riboflavin has no blood-pressure effect;
• that the TT-specific signal is definitively false;
• an appropriate individual dose.

Why level A for evidence assessment: current systematic synthesis using formal risk-of-bias and certainty methods. The certainty of the treatment effect itself remains very low.


[A6] Clinical availability of genotype and riboflavin testing

Sources:
Mayo Clinic Laboratories. Riboflavin (Vitamin B2), Plasma.
Labcorp. Vitamin B2, Whole Blood.
Major reference-laboratory MTHFR thermolabile-variant DNA assays.
Source type: current clinical laboratory test catalogs.
Used to support:

• availability of plasma and whole-blood B2 testing;
• availability of MTHFR genotyping;
• fasting and light-protection requirements for plasma riboflavin;
• elevation of plasma riboflavin after recent supplements or nonfasting intake;
• method-specific limitations.

Does not establish:

• equivalence of plasma B2, whole-blood B2, and EGRAC;
• prediction of individual MTHFR response;
• a universal reference range across laboratories.

Why level A for test availability only: primary documentation from laboratories currently performing the tests.


Moderate-confidence human intervention evidence

[B1] Riboflavin and homocysteine in MTHFR 677TT

Source:
McNulty H, Dowey LR, Strain JJ, et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C→T polymorphism. Circulation. 2006;113:74–80. PMID: 16380544.
Type: randomized, double-blind, placebo-controlled genotype-stratified trial.
Participants:

• 35 adults with 677TT;
• 26 with 677CT;
• 28 with 677CC entered the genotype-stratified intervention;
• participants received 1.6 mg/day riboflavin or placebo for 12 weeks.

What it showed:

• homocysteine fell specifically in the TT group;
• the overall TT reduction was approximately 22%;
• the reduction was approximately 40% in TT participants with the poorest initial riboflavin status;
• no corresponding homocysteine response was observed in CT or CC.

What it did not show:

• symptom improvement;
• prevention of cardiovascular events;
• superiority of R5P;
• benefit from high-dose riboflavin;
• a need for lifelong treatment;
• universal response in every TT carrier.

Why level B: direct randomized human evidence with a small genotype-defined sample and biomarker outcome.


[B2] One-carbon metabolites and riboflavin response

Source:
Rooney M, Bottiglieri T, Wasek-Patterson B, et al. Impact of the MTHFR C677T polymorphism on one-carbon metabolites: evidence from a randomised trial of riboflavin supplementation. Biochimie. 2020;173:91–99. PMID: 32330571.
Type: observational genotype comparison plus randomized intervention.
Intervention participants:

• 24 TT adults received 1.6 mg/day riboflavin;
• 23 TT adults received placebo;
• intervention lasted 16 weeks.

What it showed:

• TT was associated with higher homocysteine, lower SAM, and a lower SAM-to-SAH ratio than CC;
• riboflavin supplementation increased SAM and cystathionine in the TT intervention group;
• selected one-carbon metabolites were nutritionally modifiable.

What it did not show:

• restoration of every methylation reaction;
• symptom improvement;
• long-term clinical benefit;
• clinical utility of routine SAM or SAH testing;
• superiority of a particular supplement form.

Why level B: randomized human biomarker evidence in a small genotype-specific sample.


[B3] Targeted blood-pressure trials

Sources:
Horigan G, McNulty H, Ward M, Strain JJ, Purvis J, Scott JM. Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C→T polymorphism in MTHFR. Journal of Hypertension. 2010;28:478–486. PMID: 19952781.
Wilson CP, McNulty H, Ward M, et al. Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial. Hypertension. 2013;61:1302–1308. PMID: 23608654.
Type: genotype-targeted randomized interventions.
What they showed:

• reductions in blood pressure were reported in TT participants;
• ordinary low-dose riboflavin was used;
• the response appeared genotype specific in the studied populations.

What they did not show:

• definitive efficacy across general hypertensive populations;
• independence from all forms of bias;
• cardiovascular-event reduction;
• that riboflavin can replace medication.

Why level B: direct randomized human evidence, but from small targeted studies later judged to contribute to a very-low-certainty overall evidence base.


Limited and context-dependent evidence

[C1] SAM, SAH, and DNA-methylation interpretation

Source type: exploratory genotype comparisons and secondary biomarker analyses related to riboflavin intervention.
Used to support:

• possible changes in selected methylation-related metabolites and DNA-methylation measurements;
• biological plausibility of effects beyond homocysteine.

Does not establish:

• a clinical diagnosis of “undermethylation”;
• global tissue methylation status;
• neurological or psychiatric improvement;
• a routine indication for SAM/SAH testing.

Why level C: direct human biomarker findings with uncertain clinical meaning and limited replication.


[C2] EGRAC as a riboflavin-status biomarker

Source:
Hoey L, McNulty H, Strain JJ. Studies of biomarker responses to intervention with riboflavin: a systematic review. American Journal of Clinical Nutrition. 2009;89:1960S–1980S. PMID: 19403631.
Source type: systematic review of riboflavin-intervention biomarker studies.
Used to support:

• responsiveness of EGRAC to changes in riboflavin intake;
• usefulness of EGRAC across deficient-to-adequate populations;
• limitations of direct concentration markers.

Does not establish:

• universal clinical cutoffs;
• suitability in G6PD deficiency;
• direct measurement of MTHFR FAD occupancy;
• widespread routine availability.

Why level C for this pattern: the biomarker evidence is strong for general riboflavin status, but its ability to predict a TT-specific MTHFR response has not been validated as a routine diagnostic test.


[C3] Folate–riboflavin interaction

Source:
Moat SJ, Ashfield-Watt PAL, Powers HJ, et al. Effect of riboflavin status on the homocysteine-lowering effect of folate in relation to the MTHFR C677T polymorphism. Clinical Chemistry. 2003. PMID: 12560354.
Source type: human intervention and secondary interaction analysis.
Used to support:

• interaction between folate and riboflavin status in determining homocysteine response;
• the principle that one nutrient can modify the effect of another.

Does not establish:

• a universal folate-to-riboflavin ratio;
• that riboflavin replaces folate;
• a supplement sequence based on genotype alone.

Why level C: useful human interaction data but not a definitive individualized algorithm.


Preliminary and mechanistic evidence

[D1] Exact percentage reduction in MTHFR activity

Source type: in vitro enzyme-activity and thermolability experiments.
Used to support:

• stronger reduction in measured enzyme activity in TT than CT;
• the origin of frequently repeated residual-activity estimates.

Does not establish:

• a precise personal percentage of enzyme function;
• the percentage of folate that one person can process;
• the percentage of whole-body methylation remaining;
• the supplement dose required to compensate.

Why level D for individualized interpretation: the biochemical difference is real, but the translation of laboratory enzyme activity into a personal percentage is not validated.


Unverified explanations

[U] Popular claims not established by current evidence

The following ideas reflect real user questions but are not sufficiently supported to be treated as established conclusions:

• everyone with 677TT has a clinical methylation disorder;
• 677TT means that a person can use only 20–30% of dietary folate;
• every TT carrier requires lifelong riboflavin supplementation;
• riboflavin restores MTHFR activity to 100%;
• R5P is superior to ordinary riboflavin for 677TT;
• R5P is “methylated B2”;
• 50–400 mg is required because lower doses are too weak;
• a strong subjective reaction indicates successful enzyme activation;
• anxiety after B2 proves overmethylation;
• COMT or MAOA status predicts riboflavin tolerance;
• high serum B2 routinely means intracellular B2 deficiency;
• bright-yellow urine proves that riboflavin was not absorbed;
• riboflavin can replace folate or vitamin B12;
• riboflavin can replace antihypertensive medication;
• riboflavin prevents miscarriage or thrombosis in TT carriers;
• A1298C and 677CT should be interpreted using the same evidence as 677TT;
• improvement in mood or energy confirms that MTHFR was the cause;
• lack of symptom improvement means the dose must be increased.

These claims may contain a biochemical idea worth investigating.
They do not establish diagnosis, mechanism, dosage, clinical benefit, or safety.

The Riboflavin-Sensitive MTHFR 677TT Pattern is one of the more convincing gene–nutrient interactions within one-carbon metabolism.

Its scientific basis is specific:

The MTHFR 677TT enzyme has reduced stability and an increased tendency to lose its FAD cofactor. When riboflavin availability is inadequate, this can contribute to reduced formation of 5-MTHF and elevated homocysteine.

A randomized human trial showed that 1.6 mg/day of ordinary riboflavin lowered homocysteine specifically in adults with the TT genotype, with the largest response among those with poorer initial riboflavin status.
This makes the pattern biologically valid and practically measurable.

It does not make it unlimited.

The pattern is not established simply because:

• 677TT appears in a genetic report;
• fatigue or anxiety is present;
• methylfolate is poorly tolerated;
• COMT is slow;
• A1298C is present;
• blood pressure is high;
• a high-dose B-complex produces a strong reaction;
• bright-yellow urine appears;
• an online calculator predicts a percentage loss of methylation.

The strongest interpretation requires:

• the correct genotype;
• a compatible homocysteine phenotype;
• adequate assessment of folate and B12;
• consideration of kidney, thyroid, medication, and lifestyle factors;
• realistic evaluation of riboflavin status;
• an objective response measured under stable conditions.

The most useful question is not:

“How badly is my MTHFR mutation damaging my methylation?”

It is:

Does the 677TT genotype appear to be accompanied by a measurable, riboflavin-sensitive remethylation phenotype, and is riboflavin more plausible as a limiting factor than folate, B12, kidney function, or another explanation?